CytoDyn Inc. (OTCMKTS:CYDY – Get Free Report) shares passed below its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of $0.24 and traded as low as $0.23. CytoDyn shares last traded at $0.24, with a volume of 1,440,438 shares traded.
CytoDyn Stock Performance
The firm has a market cap of $294.52 million, a PE ratio of -23.90 and a beta of -0.28. The stock has a 50 day simple moving average of $0.24 and a two-hundred day simple moving average of $0.17.
About CytoDyn
CytoDyn Inc, a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer.
Further Reading
- Five stocks we like better than CytoDyn
- NYSE Stocks Give Investors a Variety of Quality Options
- Penny Stock SurgePays Rises 70%: 1 Reason to Buy, 5 to Sell
- What is the Shanghai Stock Exchange Composite Index?
- Top 3 Beverage Stocks Pouring Out Profits
- Consumer Discretionary Stocks Explained
- CarMax and Carvana: Steering the Used Car Market
Receive News & Ratings for CytoDyn Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytoDyn and related companies with MarketBeat.com's FREE daily email newsletter.
